IBD and Ankylosing Spondylitis: New Research Confirms the Causal Link Your Doctor May Not Have Mentioned

If you have inflammatory bowel disease and you have also been living with persistent back pain, morning stiffness, or aching in your hips and pelvis, you may have been told, or quietly assumed, that these things are unrelated. A 2026 meta-analysis published in the journal Medicine says that assumption deserves to be revisited. The study found a statistically significant, bidirectional causal association between inflammatory bowel disease and ankylosing spondylitis. IBD raises your risk of developing AS. And AS raises your risk of developing IBD.

What Ankylosing Spondylitis Is

Ankylosing spondylitis is a chronic inflammatory condition that primarily affects the spine and the sacroiliac joints, which are the joints where the pelvis meets the lower spine. In its early stages, it typically presents as deep, dull pain in the lower back or buttocks, often worse in the morning or after periods of rest, and characteristically improving with movement. This pattern of inflammatory back pain is meaningfully different from the mechanical back pain most people are familiar with.

As the condition progresses, inflammation can lead to new bone formation along the spine. In some cases, this can cause vertebrae to fuse, reducing spinal mobility. The condition belongs to a broader family of inflammatory joint diseases called spondyloarthropathies, which also includes psoriatic arthritis and reactive arthritis. All of these conditions share some genetic risk factors with IBD.

Why IBD Patients Are at Higher Risk

Extraintestinal manifestations (disease complications that occur outside the gut) are common in IBD. The NHS describes joint problems as one of the most frequent of these, noting they can affect both the peripheral joints of the arms and legs and the axial skeleton, including the spine and sacroiliac joints. Some joint manifestations are directly linked to bowel activity and improve when IBD is brought under control. Others follow their own course regardless of gut disease activity, which is particularly true of axial spondyloarthropathy.

The biological reasons for this connection include shared genetic risk factors, particularly the HLA-B27 gene variant, which is strongly associated with ankylosing spondylitis and also elevated in certain IBD subgroups, as well as shared immune system pathways, particularly involving the interleukin-17 and interleukin-23 axis, which is already a target of several IBD treatments.

What the 2026 Study Found

The meta-analysis published in Medicine on 31 July 2026 (Guo J, Qiao Y, Li H; pubmed:42536573) combined two methodological approaches to examine whether the IBD-ankylosing spondylitis relationship is genuinely causal.

The first approach was Mendelian randomization. This technique uses genetic variants present from birth as natural instrumental variables. Because genetics are determined before any disease develops and are largely independent of lifestyle and environmental factors, using them as proxies allows researchers to test causal effects more rigorously than standard observational methods. The authors applied Mendelian randomization using an independent genetic database, specifically one drawn from a different cohort than previous studies on this question, providing an additional layer of validation.

The second approach was a conventional meta-analysis of observational studies, pooling data across multiple study populations to produce a combined effect estimate.

Both approaches reached the same conclusion: the association is bidirectional and statistically significant. IBD confers elevated ankylosing spondylitis risk. Ankylosing spondylitis confers elevated IBD risk. The genetic evidence supported a causal interpretation, meaning the link is unlikely to be explained by shared confounders alone.

What This Means in Practice

For IBD patients, this finding has several practical implications.

First, it means that joint symptoms, particularly inflammatory patterns of back pain and stiffness, are not just incidental or unrelated noise. They are part of the IBD landscape, and they deserve clinical attention, not dismissal. Spondyloarthropathy is both treatable and relevant to IBD management.

Second, it means that the biological mechanisms driving your IBD may be the same mechanisms affecting your joints. Several newer IBD biologics, particularly those targeting the IL-23 and IL-17 pathways, also have efficacy in spondyloarthropathy. This overlap is clinically relevant when treatment decisions are being made.

Third, for people with ankylosing spondylitis who do not have a known IBD diagnosis, the bidirectionality of the association is a reminder that subclinical gut inflammation is common in AS, far more common than frank IBD diagnosis rates would suggest. If you have AS and notice persistent digestive symptoms, this warrants discussion with your rheumatologist.

What to Look For

The following symptoms, in the context of an IBD diagnosis, warrant discussion with your IBD care team or gastroenterologist:

• Dull, deep pain in the lower back or buttocks lasting more than three months
• Morning stiffness lasting more than 30 minutes that improves with movement and worsens with rest
• Pain that wakes you from sleep and is relieved by getting up and moving
• Reduced range of motion in the spine over time
• Swelling, pain, or stiffness in the hips or shoulders

These are the clinical hallmarks of inflammatory back pain, as distinguished from mechanical back pain. They can be present for years before a formal diagnosis is made, and many IBD patients live with them without connecting them to their bowel condition.

What to Do

If any of the above patterns are familiar to you, the most important step is to mention them at your next IBD appointment, or contact your IBD nurse or GP sooner if they are significantly affecting your daily life. A diagnosis of spondyloarthropathy requires clinical assessment, imaging, and sometimes specialist rheumatology input. It cannot be confirmed or excluded based on any single article.

What this 2026 meta-analysis adds to the existing body of evidence is further confirmation that the link is not coincidental. If you have IBD, your joints are part of the clinical picture.